Tyra Biosciences announced a $400 million underwritten offering of common stock and pre-funded warrants priced at about $22 per share. The proceeds will support development of their lead drug candidate dabogratinib for cancers and achondroplasia, as well as other preclinical programs and general corporate purposes. The offering is expected to close on September 15, 2026, with participation from major institutional investors. This capital raise aims to advance Tyra's precision medicine pipeline targeting FGFR biology in oncology and genetic conditions.
Vannor introduced an agentic marketing model featuring autonomous AI agents that independently manage marketing tasks from research to content publication and optimization. Running on Vannor-owned NVIDIA AI hardware, these agents increased the compan...
Bitcoin's price increased to $83,022 in spot trading on Binance as of October 10, marking a $200 gain within 15 minutes and a 0.22% rise from an hour earlier. This uptick reflects continued interest and momentum in the largest cryptocurrency by marke...
Broadcom, Marvell, and AMD are benefiting from rising AI-related semiconductor demand, with shares up significantly in 2026. Analysts project bold price targets for 2027, suggesting potential gains around 60% for each stock, driven by strong earnings...
Ether (ETH), the second-largest cryptocurrency by market cap, surpassed the key price level of $2,500 on October 10, trading at $2,504 at 10:28 a.m. ET. This marks a slight increase from $2,498 just 15 minutes earlier and reflects a 0.19% gain from a...
Ether (ETH) traded above the $2,500 mark, reaching 2,500.05 USDT as of 10:26 a.m. ET on October 10. The price increased by 0.36% over the previous 24 hours, indicating a modest gain. No specific market catalyst or future price signals were reported a...
